TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Protagenic Therapeutics ( (PTIX) ) just unveiled an announcement.
On November 20, 2025, Protagenic Therapeutics received a notification from Nasdaq indicating non-compliance with listing rules due to insufficient stockholders’ equity and delayed filing of a quarterly report. The company plans to appeal the delisting decision and has requested a hearing, during which its stock will continue to trade on Nasdaq. However, there is no assurance that the appeal will be successful or that compliance will be regained.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological and neuropsychiatric conditions.
Average Trading Volume: 94,754
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.3M
For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.